CTOR
Citius Oncology
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About CTOR
Citius Oncology, Inc.
New targeted tumor therapy development company
Life Science Tools and Services
03/01/2021
12/08/2022
NASDAQ Stock Exchange
0
09-30
Common stock
11 Commerce Drive, First Floor, Cranford, NJ 07016
--
Citius Oncology, Inc. (formerly TenX Keane Acquisition) was incorporated in the Cayman Islands on March 1, 2021, and was relocated and naturalized as a Delaware company on August 5, 2024. Citius Oncology will serve as a platform to develop and commercialize novel targeted tumor therapies. In August 2024, its main asset, LYMPHIR, received FDA approval for the treatment of adult patients with relapsed or refractory CTCL who have received at least one systemic treatment.
Company Financials
EPS
CTOR has released its 2025 Q2 earnings. EPS was reported at -0.11, versus the expected -0.09, missing expectations. The chart below visualizes how CTOR has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
